ViAqua Therapeutics was established to address the growing need for effective, specific, and affordable health management of diseases in aquaculture. ViAqua is developing a biotechnology-based, oral delivery platform for targeted administration of nucleic acid-based therapeutics. ViAqua’s first product is an RNA-based solution for application against the White Spot Shrimp Virus (WSSV) pandemic.